With aging populations worldwide, degenerative eye diseases like age-related macular degeneration (AMD) are becoming more common, and yet, curative treatments remain out of reach. In an exclusive conversation with Zane Wu (Tzu-Heng Wu), CEO of 創生醫電 PlasmonicTron, GeneOnline explores how this biotech is working to change that by advancing retinal organoid technology from concept to clinic.
Using induced pluripotent stem cells (iPSCs), PlasmonicTron is developing functional retinal organoids for transplantation and drug screening. Backed by AI-driven quality control, the company aims to bring consistency, safety, and scalability to a field long held back by technical and regulatory hurdles.
Learn how this biotech is merging regenerative medicine, AI, and clinical urgency to light the path forward: https://bit.ly/4oq1iUk
